Sickle Cell Pain: Intervention With Capsaicin Exposure (SPICE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03899246|
Recruitment Status : Completed
First Posted : April 2, 2019
Last Update Posted : July 29, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Neuropathic Pain Sickle Cell Disease||Drug: Eight Percent Topical Capsaicin||Phase 1|
Patients with sickle cell disease suffer debilitating painful episodes, as well as chronic, often daily, pain that are commonly treated with non-steroidal anti-inflammatory drugs, opioids, and other non-pharmacologic supportive measures. Neuropathic pain has been shown to be present in these patients, with frequency increasing with age. It is believed, based on knowledge of neuropathic pain related to other conditions and from the small number of studies in sickle cell patients, to result from repeated vaso-occlusive pain episodes that prime central and peripheral pain sensing pathways in a maladaptive manner, leading to hyper-sensitization. Very few studies to date have evaluated therapies specifically targeting this aspect of the pain experienced by patients with sickle cell disease.
This is a pilot study for a future longitudinal study of neuropathic pain in pediatric patients with sickle cell disease. The first aim of this pilot study is to establish the safety of treating participants with sickle cell disease aged fourteen to twenty-one with eight percent topical capsaicin patches on an every three-month dosing schedule as recommended by the manufacturer. This will be a single-arm safety study. Presence of neuropathic pain will be determined by day zero evaluation via the testing shown in the outcome measures below. Topical medication will be administered over one hour, every three months, for six months (total of three applications), to sites of recurrent vaso-occlusive pain, according to the package insert administration guidelines. Subjective and objective evaluations of pain and inflammation including questionnaires, blood tests, and quantitative sensory testing will be carried out every six weeks throughout the study period until twelve weeks after the final capsaicin application. Additionally, participants will record daily pain and medication use in a mobile app. Safety will be established by there being no grade three or four adverse events according to CTCAE definitions. Grade two adverse events will be evaluated on a case by case basis throughout the duration of the study. Feasibility of monitoring neuropathic pain with the aforementioned studies will be established by participant compliance with greater than eighty percent of all study activities.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Single arm, safety and feasibility trial assessing the suitability of an FDA approved medication for use in children with an off-label condition.|
|Masking:||None (Open Label)|
|Official Title:||Safety and Feasibility of High-Dose Topical Capsaicin for the Treatment of Neuropathic Pain in Pediatric Sickle Cell Disease|
|Actual Study Start Date :||July 3, 2019|
|Actual Primary Completion Date :||March 30, 2020|
|Actual Study Completion Date :||March 30, 2020|
Experimental: Capsaicin Arm
Single arm to receive eight percent topical capsaicin applied to up to 4 sites of recurrent pain over one hour on an every three month schedule. Participants in this arm will receive pretreatment with topical five percent lidocaine.
Drug: Eight Percent Topical Capsaicin
See arm description
Other Name: Qutenza
- Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE Criteria [ Time Frame: At the end of the 9 month study period all participant information will be reviewed and adverse events assessed. ]Safety will be established by there being no treatment-related adverse events greater than grade 2 using CTCAE definitions of adverse events. Grade 2 CTCAE events will be evaluated on a case by case basis to determine safety of continuing the study. Grade 3 events will result in immediate suspension of study activities until a full analysis of the event in question is completed.
- Compliance with Serum Substance P Levels [ Time Frame: At the end of the 9 month study period all participant information will be reviewed and compliance with testing assessed. ]Feasibility will be established by participants having greater than 80 percent compliance with all study investigations, including serum substance P levels.
- Compliance with Subjective Neuropathic Pain Questionnaire [ Time Frame: At the end of the 9 month study period all participant information will be reviewed and compliance with testing assessed. ]Feasibility will be established by participants having greater than 80 percent compliance with all study investigations, including completion of PainDETECT Questionnaire during study visits. The questionnaire is a validated assessment of neuropathic pain. It consists of a series of questions regarding the experience of pain for which the participant will provide an answer ranging from "never" (0 points) to "very strongly" (5 points). Points are added to provide a total score from 0 to 38. A score from 0 to 12 indicates a neuropathic pain component is unlikely, a score of 12 to 18 is equivocal, and a score greater than 18 indicates a neuropathic component is likely.
- Compliance with Quantitative Sensory Testing [ Time Frame: At the end of the 9 month study period all participant information will be reviewed and compliance with testing assessed. ]Feasibility will be established by participants having greater than 80 percent compliance with all study investigations, including quantitative sensory testing using electronic von frey machine.
- Compliance with Mobile App Record Keeping [ Time Frame: Duration of study period (9 months). Mobile app recordings can be reviewed in real time and will be recorded on a weekly basis. ]Feasibility, as above, will be established by greater than 80 percent compliance with daily mobile app recordings of pain and home medication use.
- Compliance with Blood Draws for Hyperspectral Imaging Analysis for Determining Presence and Improvement of Chronic Neuropathic Pain [ Time Frame: Duration of study period (9 months). Will be drawn and processed at 6 week intervals throughout the study period. ]Feasibility will be established by the successful processing of greater than 80 percent of target number of blood samples to be sent for hyperspectral analysis, a novel test capable of detecting chronic pain states, but not yet used in the sickle cell population.
- Morphine Equivalents Utilized [ Time Frame: Duration of study period (9 months). Will be evaluated at 6 week intervals throughout the study period. ]Will assess changes in pain medication required during the course of the study period based on electronic medical record, participant report, and controlled substance monitoring database.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||14 Years to 21 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- A diagnosis of either Sickle Cell Disease with genotype SS or S Beta-zero, or SC disease.
- Must have recurrent sites of pain, where majority of acute pain episodes are localized
- Subjects are willing and able to comply with scheduled visits, treatment plan, laboratory tests, pain assessments, and other study procedures.
- Subjects who are being treated with hydroxyurea (HU) must have been on a stable dose for at least 8 weeks prior to Visit 1 (Day 0), with the intent of remaining on the same dose of hydroxyurea throughout the clinical trial including the protocol-specified follow-up period unless adjustments are medically necessary due to bone marrow suppression.
- At least 80% compliance (defined as logging pain at least once daily) with mobile application use during 14-day lead in period from time of enrollment to time of first capsaicin application.
- Age less than 14 or greater than 21
- History of major surgery within the past 3 months.
- Patients receiving scheduled chronic partial exchange transfusions as part of their sickle cell disease management protocol.
- Concurrently taking another medication used in the treatment of neuropathic pain or with the potential to affect the peripheral nervous system (e.g. gabapentin, anti-epileptics, antidepressants, systemic alpha or beta adrenergic receptor blockers)
- Use of another topical analgesic at home in the treatment of pain episodes such as topical lidocaine, diclofenac, or menthol (must discontinue use at the time of enrollment).
- Recurrent pain secondary to an underlying condition other than vaso-occlusive pain (avascular necrosis, scoliosis, fracture, etc.)
- Patients lacking the mental capacity to assent to the study
- Patients with another chronic inflammatory/immune disorder that could skew the inflammatory markers listed above.
- Pregnant females
- Expectation that the subject will not be able to be followed for the duration of the study
- Active use of illicit drugs and/or alcohol dependence, as determined by the investigator. Opioid use beyond the amount necessary for pain related to the underlying sickle cell disease as determined by the investigator.
- Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03899246
|United States, Michigan|
|Children's Hospital of Michigan|
|Detroit, Michigan, United States, 48201|
|Principal Investigator:||Alexander K Glaros, MD||Children's Hospital of Michigan|
|Principal Investigator:||Ahmar U Zaidi, MD||Children's Hospital of Michigan|
|Principal Investigator:||Callaghan Michael, MD||Children's Hospital of Michigan|
|Responsible Party:||Alexander Glaros, Pediatric Hematology-Oncology Fellow, Children's Hospital of Michigan|
|Other Study ID Numbers:||
|First Posted:||April 2, 2019 Key Record Dates|
|Last Update Posted:||July 29, 2020|
|Last Verified:||July 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Quantitative Sensory Testing
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Peripheral Nervous System Diseases
Nervous System Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs